DE69217614D1 - Hybride, lösliche und nicht gespaltene gp160-variante - Google Patents

Hybride, lösliche und nicht gespaltene gp160-variante

Info

Publication number
DE69217614D1
DE69217614D1 DE69217614T DE69217614T DE69217614D1 DE 69217614 D1 DE69217614 D1 DE 69217614D1 DE 69217614 T DE69217614 T DE 69217614T DE 69217614 T DE69217614 T DE 69217614T DE 69217614 D1 DE69217614 D1 DE 69217614D1
Authority
DE
Germany
Prior art keywords
hiv
region
strain
soluble
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69217614T
Other languages
English (en)
Other versions
DE69217614T2 (de
Inventor
Marie-Paule Kieny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Publication of DE69217614D1 publication Critical patent/DE69217614D1/de
Application granted granted Critical
Publication of DE69217614T2 publication Critical patent/DE69217614T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE69217614T 1991-05-02 1992-04-30 Hybride, lösliche und nicht gespaltene gp160-variante Expired - Lifetime DE69217614T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR919105392A FR2676071B1 (fr) 1991-05-02 1991-05-02 Nouveau variant gp160 non-clivable, soluble, de forme hybride.
PCT/FR1992/000394 WO1992019742A1 (fr) 1991-05-02 1992-04-30 NOUVEAU VARIANT gp160 NON-CLIVABLE, SOLUBLE, DE FORME HYBRIDE

Publications (2)

Publication Number Publication Date
DE69217614D1 true DE69217614D1 (de) 1997-04-03
DE69217614T2 DE69217614T2 (de) 1997-07-10

Family

ID=9412448

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69217614T Expired - Lifetime DE69217614T2 (de) 1991-05-02 1992-04-30 Hybride, lösliche und nicht gespaltene gp160-variante

Country Status (12)

Country Link
US (2) US6261799B1 (de)
EP (1) EP0541753B1 (de)
JP (1) JP3453611B2 (de)
AT (1) ATE149203T1 (de)
CA (1) CA2086509C (de)
DE (1) DE69217614T2 (de)
DK (1) DK0541753T3 (de)
ES (1) ES2099257T3 (de)
FR (1) FR2676071B1 (de)
GR (1) GR3023070T3 (de)
SG (1) SG44828A1 (de)
WO (1) WO1992019742A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59309207D1 (de) * 1992-10-06 1999-01-21 Dade Behring Marburg Gmbh Retrovirus aus der HIV-Gruppe und dessen Verwendung
WO1994016081A1 (de) * 1993-01-16 1994-07-21 Manfred Schawaller Verfahren zur gewinnung nativer domänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
NZ520754A (en) 2000-02-10 2004-02-27 Panacos Pharmaceuticals Inc Identifying compounds that disrupt formation of critical gp41 six-helix bundle and conformations necessary for HIV entry thereby blocking virus entry to the cell
WO2009011912A1 (en) * 2007-07-18 2009-01-22 Bristol-Myers Squibb Company A composition for treating hiv comprising virus-like particles
CA2834288A1 (en) * 2011-04-25 2012-11-01 Advanced Bioscience Laboratories, Inc. Truncated hiv envelope proteins (env), methods and compositions related thereto
EP2869842A1 (de) * 2012-07-06 2015-05-13 Novartis AG Immunogene zusammensetzungen und verwendungen davon
WO2016196471A1 (en) 2015-06-02 2016-12-08 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
EP3504225B1 (de) 2017-11-17 2024-04-24 Grifols Diagnostic Solutions Inc. Neue, in säugetieren exprimierte hüllprotein-antigene des humanen immunschwächevirus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2606029B2 (fr) * 1986-04-08 1989-02-03 Transgene Sa Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus
US5169763A (en) * 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
JPS63258575A (ja) * 1986-12-15 1988-10-26 レプリゲン　コーポレーション 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
EP0469089B1 (de) * 1989-04-18 1997-11-19 Applied Biotechnology, Inc. Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren
FR2650954B1 (fr) * 1989-08-18 1992-02-28 Pasteur Institut Composition resultant de la reunion d'un epitope b de la glycoproteine d'enveloppe d'un retrovirus du type iv et d'un epitope t issu d'une proteine distincte codee par ce retrovirus et leur application a la production d'anticorps protecteurs contre le sida
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
IE904083A1 (en) * 1989-11-13 1991-05-22 Cambridge Biotech Corp Diagnostic proteins to test for more than one antibody
ATE125157T1 (de) * 1990-04-03 1995-08-15 Genentech Inc Methoden und zusammensetzungen zur impfung gegen hiv.

Also Published As

Publication number Publication date
CA2086509C (fr) 2003-07-01
JP3453611B2 (ja) 2003-10-06
GR3023070T3 (en) 1997-07-30
CA2086509A1 (fr) 1992-11-03
JPH05508324A (ja) 1993-11-25
WO1992019742A1 (fr) 1992-11-12
US6261799B1 (en) 2001-07-17
FR2676071B1 (fr) 1994-11-18
DK0541753T3 (da) 1997-08-04
EP0541753B1 (de) 1997-02-26
DE69217614T2 (de) 1997-07-10
US6284248B1 (en) 2001-09-04
ATE149203T1 (de) 1997-03-15
FR2676071A1 (fr) 1992-11-06
EP0541753A1 (de) 1993-05-19
SG44828A1 (en) 1997-12-19
ES2099257T3 (es) 1997-05-16

Similar Documents

Publication Publication Date Title
DE60037450D1 (de) Funf-helix protein
NO20025153L (no) Fremgangsmåter og sammensetninger for å påvirke formering av HIV-1, HIV-2 og SIV
DK1240186T3 (da) Forbedringer i eller relateret til immunrespons mod HIV
DE3855947D1 (de) Peptide mit den immunologischen Eigenschaften von HIV-2
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
DE60039036D1 (de) Hiv-peptide, antigene und impfstoffzusammensetzungen
DE69217614D1 (de) Hybride, lösliche und nicht gespaltene gp160-variante
Nygren et al. 95-and 25-kDa fragments of the human immunodeficiency virus envelope glycoprotein gp120 bind to the CD4 receptor.
EP0255190A3 (de) Rekombinante Polypeptide und ihre Verwendungen sowie Test für den AIDS-Virus
WO1993018055A3 (en) Peptides stimulating cytotoxic lymphocytes respone to hiv-1 gp160
DE69231705T2 (de) Gag-Env Fusion-Antigen aus HIV
DE69941051D1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier
ES8800358A1 (es) Un procedimiento para preparar un polipeptido hibrido.
ES2074591T3 (es) Expresion de polipeptidos de vih 1 y 2 y su utilizacion.
GB2336844A (en) Anti-hiv peptides and proteins
ES2095899T3 (es) Peptidos de la proteina gag de vih, su preparacion y uso.
RU2221873C2 (ru) Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
DK284389A (da) Precursorantigener
KR890003946A (ko) 인간 면역 결핍 비루스 타입1의 항원의 제조방법 및 진단 및 치료제로서의 이의 용도
OA08716A (fr) Peptides susceptibles d'être reconnus par des anticorps induits contre des retrovirus d'immunodéficience humaine (virus HIV), leurs applications au diagnostic des infections dues à certains de ces virus et, le cas échéant, à la vaccination contre le sida.
RU2000106709A (ru) Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5
TH13136EX (th) แอนติเจนของ hiv

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 541753

Country of ref document: EP